Addition of salmeterol to usual asthma pharmacotherapy may increase respiratory related deaths or life threatening experiences

doi:10.1136/ebm.11.5.139

Article Text

Therapeutics

Addition of salmeterol to usual asthma pharmacotherapy may increase respiratory related deaths or life threatening experiences

https://doi.org/10.1136/ebm.11.5.139

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

↵* Information provided by author.
↵† See glossary.
↵‡ GSK Clinical Trials Registry. http://ctr.glaxowellcome.co.uk/Summary/salmeterol/studylist.asp (SLGA5011 SMART) (accessed 24 Jul 06).
For correspondence: Dr P M Dorinsky, GlaxoSmithKline, Research Triangle Park, NC, USA. Paul.m.dorinsky{at}gsk.com
Source of funding: GlaxoSmithKline.

Linked Articles

Glossary
Glossary

BMJ Publishing Group Ltd
BMJ Evidence-Based Medicine 2006; 11 159a-159a Published Online First: 29 Sep 2006. doi: 10.1136/ebm.11.5.159a

Log in using your username and password

Main menu

Log in using your username and password

You are here

Statistics from Altmetric.com

Request Permissions

Footnotes

Linked Articles

Read the full text or download the PDF:

Log in using your username and password

Read the full text or download the PDF:

Log in using your username and password